1. Home
  2. MLYS vs ICHR Comparison

MLYS vs ICHR Comparison

Compare MLYS & ICHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$59.41

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
ICHR
Founded
2019
1999
Country
United States
United States
Employees
N/A
2448
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
MLYS
ICHR
Price
$25.85
$59.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$48.67
★ $49.50
AVG Volume (30 Days)
★ 1.2M
572.8K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $947,652,000.00
Revenue This Year
N/A
$20.51
Revenue Next Year
N/A
$17.08
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 11.61
52 Week Low
$22.30
$14.06
52 Week High
$47.65
$113.58

Technical Indicators

Market Signals
Indicator
MLYS
ICHR
Relative Strength Index (RSI) 39.48 50.34
Support Level $22.36 $56.60
Resistance Level $31.36 $59.00
Average True Range (ATR) 1.48 2.31
MACD -0.40 1.27
Stochastic Oscillator 5.09 88.79

Price Performance

Historical Comparison
MLYS
ICHR

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About ICHR Ichor Holdings

Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.

Share on Social Networks: